SCHEMBL3011444

SCHEMBL3011444

COc1ccc(-c2csc(N3CCN(S(=O)(=O)c4ccc(OC)cc4OC)CC3)n2)c(OC)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.53
RECQL P46063 2/20 0.53
USP2 O75604 1/20 0.53
HSD17B10 Q99714 1/20 0.53
CYP1A1 P04798 1/20 0.51
CYP1B1 Q16678 1/20 0.51
AR P10275 1/20 0.51
POLB P06746 1/20 0.49
REV1 Q9UBZ9 1/20 0.49
KMT2A Q03164 5/20 0.47
RAB9A P51151 4/20 0.46
MEN1 O00255 3/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
NPC1 O15118 3/20 0.46
NFKB1 P19838 2/20 0.46
NFKB2 Q00653 2/20 0.46
RELA Q04206 2/20 0.46
ATM Q13315 1/20 0.46
TP53 P04637 1/20 0.46
ALDH1A1 P00352 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3008901 0.93 MAPT (0.55) MAPTRECQLUSP2HSD17B10AR
SCHEMBL3010407 0.93 REV1 (0.57) MAPTRECQLUSP2HSD17B10AR
SCHEMBL3010901 0.93 KMT2A (0.57) MAPTRECQLUSP2HSD17B10CYP1A1
SCHEMBL3017059 0.91 MAPT (0.49) MAPTRECQLUSP2HSD17B10CYP1A1
SCHEMBL3004366 0.91 AR (0.53) MAPTRECQLUSP2HSD17B10AR
SCHEMBL3018756 0.90 MAPT (0.63) MAPTRECQLUSP2HSD17B10CYP1A1
SCHEMBL3014348 0.90 POLB (0.59) MAPTRECQLUSP2HSD17B10CYP1A1
SCHEMBL3014610 0.90 AR (0.57) MAPTRECQLUSP2HSD17B10CYP1A1
SCHEMBL3014233 0.89 MAPT (0.54) MAPTRECQLUSP2HSD17B10POLB
SCHEMBL3011256 0.89 MAPT (0.51) MAPTRECQLUSP2HSD17B10CYP1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885RECQL 1564/4885USP2 1831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.